|
| Targeted drug combination therapy design based on driver genes |
|
https://doi.org/10.18632/oncotarget.26985
Lilian Zsákai, Anna Sipos, Judit Dobos, Dániel Erős, Csaba Szántai-Kis, Péter Bánhegyi, János Pató, László Őrfi, Zsolt Matula, Gábor Mikala, György Kéri, István Peták, István Vályi-Nagy
|
| 5255-5266 |
|
| Deep insights into the response of human cervical carcinoma cells to a new cyano enone-bearing triterpenoid soloxolone methyl: a transcriptome analysis |
|
https://doi.org/10.18632/oncotarget.27085
Andrey V. Markov, Alexander E. Kel, Oksana V. Salomatina, Nariman F. Salakhutdinov, Marina A. Zenkova, Evgeniya B. Logashenko
|
| 5267-5297 |
|
| Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells |
|
https://doi.org/10.18632/oncotarget.27112
Piyush More, Ute Goedtel-Armbrust, Viral Shah, Marianne Mathaes, Thomas Kindler, Miguel A. Andrade-Navarro, Leszek Wojnowski
|
| 5298-5312 |
|
| Genome-wide miRNA profiling and pivotal roles of miRs 125a-5p and 17-92 cluster in human neutrophil maturation and differentiation of acute myeloid leukemia cells |
|
https://doi.org/10.18632/oncotarget.27123
El-Habib Dakir, Faustino Mollinedo
|
| 5313-5331 |
|
| Safety evaluation of conditionally immortalized cells for renal replacement therapy |
|
https://doi.org/10.18632/oncotarget.27152
Milos Mihajlovic, Sam Hariri, Koen C.G. Westphal, Manoe J. Janssen, Miriam J. Oost, Laura Bongiovanni, Lambertus P. van den Heuvel, Alain de Bruin, Luuk B. Hilbrands, Rosalinde Masereeuw
|
| 5332-5348 |
|
| Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.27160
Maud-Emmanuelle Gilles, Liangliang Hao, Kaelyn Brown, Jihoon Lim, Sangeeta N. Bhatia, Frank J. Slack
|
| 5349-5358 |
|
| Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines |
|
https://doi.org/10.18632/oncotarget.27164
Robert O. Dillman, Gabriel I. Nistor, Bryce T. McLelland, Candace Hsieh, Aleksandra J. Poole, Andrew N. Cornforth, Hans S. Keirstead
|
| 5359-5371 |
|
| A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation |
|
https://doi.org/10.18632/oncotarget.27166
Henning Karlsson, Wojciech Senkowski, Mårten Fryknäs, Sharmineh Mansoori, Stig Linder, Joachim Gullbo, Rolf Larsson, Peter Nygren
|
| 5372-5382 |
|
| Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms |
|
https://doi.org/10.18632/oncotarget.27175
Tri Nguyen, Rebecca Parker, Elisa Hawkins, Beata Holkova, Victor Yazbeck, Akhil Kolluri, Maciej Kmieciak, Mohamed Rahmani, Steven Grant
|
| 5383-5384 |
|
| Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer |
|
https://doi.org/10.18632/oncotarget.27186
Mohamed A. Ahmed, Edgar Selzer, Wolfgang Dörr, Gerd Jomrich, Felix Harpain, Gerd R. Silberhumer, Leonhard Müllauer, Klaus Holzmann, Bettina Grasl-Kraupp, Michael Grusch, Walter Berger, Brigitte Marian
|
| 5385-5386 |
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
